Drugs
Conditions
News and resources
MIMS Supported ResourcesThe TNF-alpha inhibitor should be used only when the response to conventional therapy, including a corticosteroid and/or an immunosuppressant, is inadequate or when such therapies are not tolerated or are contraindicated.
Further information: AbbVie
Humira approved for use in moderate Crohn's disease
The licensed indications for Humira (adalimumab) have been extended to include the treatment of adults with moderately active Crohn's disease, in addition to use in severe disease.
Want news like this straight to your inbox?
Sign up for our bulletinsRead these next
In Depth | Entyvio: gut-selective immunosuppressant for inflammatory bowel disease
Takeda has launched Entyvio (vedolizumab) for the treatment...
TNF inhibitors: prescribers reminded of tuberculosis risk
The MHRA has issued a reminder to prescribers regarding...
Humira licensed for paediatric Crohn's
The licensed indications for Humira (adalimumab) have...
Further licence extension for adalimumab in arthritis
Humira is the first biologic specifically licensed...
Humira: new treatment option for ulcerative colitis
Humira (adalimumab) can now be prescribed for the treatment...
